Precision NanoSystems Announces New Cell Therapy Reagent for Lipid Nanoparticle-based mRNA Delivery to T Cells

Press Release

April 20, 2021

The GenVoy-ILM T Cell Kit for mRNA uses LNP designed to exploit endogenous uptake pathways to efficiently deliver mRNA into activated human primary T cells to mediate titratable, uniform protein expression levels with high cell viability. The mRNA-LNP are also compatible with established T cell culture media allowing rapid integration into existing workflows. The combination of non-disruptive mRNA delivery technology and seamless integration with cell culture protocols eliminates cell recovery times post-treatment to accelerate the production of T cell therapies.

 “The COVID-19 mRNA-LNP vaccines have demonstrated the power of lipid nanoparticle technology for the rapid development of highly effective genetic medicines,” said Dr. James Taylor, CEO & cofounder of PNI. “PNI believes that LNP technology can also accelerate the development of transformative cell therapies and we are thrilled to launch a LNP reagent kit specifically designed for the efficient delivery of mRNA into T cells using PNI’s proprietary GenVoy-ILM delivery platform.”

Dr. Angelo Cardoso, Director of the Laboratory for Cellular Medicine at the Beckman Research Institute at City of Hope, also expressed excitement about PNI’s launch of GenVoy-ILM T Cell Kit for mRNA, “LNP designed for defined cell types open new opportunities for the manufacture of gene-edited cell therapies and, hopefully in the future, in vivo gene targeting.”

Learn more about the GenVoy-ILM T Cell Kit for mRNA by registering for our upcoming webinars on May 6th and May 11th. And join us at the American Society of Gene & Cell Therapy Annual Meeting for a PNI sponsored symposium “Accelerating Genetic Medicine Development with Lipid Nanoparticles" at 2-3:30 PM ET on May 13th, 2021.


Learn more about those events at


Learn more about Precision NanoSystems and the GenVoy-ILM T Cell Kit for mRNA at GenVoy-ILM T Cell Kit for mRNA

About Precision NanoSystems Inc. (PNI)

PNI is a global leader ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug researchers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.


Press Release

Cytiva has completed its integration of the Precision NanoSystems business

Read More

Press Release

Cytiva, a global life sciences leader, has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines. Fully compliant and offering automated instrumentation, the NanoAssemblr commercial formula...
Read More